Reporter brief
GLP-1 agonists associated with lower all-cause mortality and ascites in MASH patients: propensity-matched cohort study
What happened
A retrospective cohort study of 1.4 million adults with metabolic dysfunction-associated steatohepatitis (MASH) examined clinical outcomes in 168,733 GLP-1 receptor agonist users versus matched non-users. GLP-1 RA exposure was associated with reduced all-cause mortality (RD −0.022) and lower ascites incidence (RD −0.013), though a statistically significant but clinically negligible increase in hepatocellular carcinoma was detected (RD 0.000).
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Cohort; Human.
Adults with metabolic dysfunction-associated steatohepatitis (MASH)
- Design
- Cohort
- Sample
- 337,466
- Journal
- Medicine
- Published
- Sep 11, 2026
Effect size
Ascites: RD −0.013 (95% CI −0.014 to −0.012); All-cause mortality: RD −0.022 (95% CI −0.023 to −0.021); HCC: RD 0.000 (95% CI 0.000–0.001)
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.